FDA
-
-
-
-
-
-
-
Psyence BioMed reports GMP-compliant ibogaine inventory for research
-
-
-
-
-
-
-
Psyence BioMed exports psilocybin to Australia for Phase IIb trial
-
-
-
-
-
-
-
Psyence BioMed sets Feb. 2 effective date for reverse stock split
-
-
-
-
-
-
-
Psyence BioMed authorizes share buyback program
-
-
-
-
-
-
-
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program
-
-
-
-
-
-
-
Psyence BioMed invests $3.5 million in psychedelic supplier PsyLabs
-
-
-
-
-
-
-
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
-
330,138 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

